4//SEC Filing
Chesworth Richard 4
Accession 0001209191-21-053642
CIK 0001815442other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 4:55 PM ET
Size
9.1 KB
Accession
0001209191-21-053642
Insider Transaction Report
Form 4
Chesworth Richard
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-27$20.00/sh+33,779$675,580→ 33,779 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-08-27−33,779→ 263,340 totalExercise: $20.00Exp: 2030-08-19→ Common Stock (33,779 underlying) - Sale
Common Stock
2021-08-27$60.12/sh−33,779$2,030,864→ 0 total
Footnotes (3)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821188
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 4:55 PM ET
- Size
- 9.1 KB